BEIJING, June 5, 2025 /PRNewswire/ — Yiren Digital Ltd. (NYSE: YRD) ("Yiren Digital"), an AI-powered platform providing a comprehensive suite of financial and lifestyle services in Asia, announced that it plans to release its unaudited financial results for the first quarter ended March 31, 2025 before U.S. market opens on Thursday, June 12, 2025.

Yiren Digital’s management will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on June 12, 2025 (or 8:00 p.m. Beijing/Hong Kong Time on June 12, 2025).

Participants who wish to join the call should register online in advance of the conference at: https://dpregister.com/sreg/10200245/ff3e415b7a

Once registration is completed, participants will receive the dial-in details for the conference call.

Additionally, a live and archived webcast of the conference call will be available at https://event.choruscall.com/mediaframe/webcast.html?webcastid=ZoyvDsQv

About Yiren Digital

Yiren Digital Ltd. is an advanced, AI-powered platform providing a comprehensive suite of financial and lifestyle services in Asia. Our mission is to elevate customers’ financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. We support clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.

 

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Casual Films Celebrated Among Winners – KuCoin's Brand Film Wins Top Honors at the 2025 MUSE Creative Awards: Season 2

PROVIDENCIALES, Turks and Caicos Islands, Oct. 21, 2025 /PRNewswire/ — The 2025 MUSE…

Kuaishou Technology Announces Fourth Quarter and Full Year 2025 Financial Results

HONG KONG, March 25, 2026 /PRNewswire/ — Kuaishou Technology ("Kuaishou" or the "Company";…

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the…